GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

Table 6 Change in clinical outcomes from baseline to weeks 9-12 in the 34 patients with prior anti-CGRP mAb treatment failure among the 82 who completed the 12-week follow-up

Clinical outcomes	Baseline	Week 9-12	Δ	p-value^*
MMD/MHD	21.5±7.7	12.6±9.5	-8.9±7.3	<0.001
MAI	19.5±10.6	9.4±9.2	-9.8±9.7	<0.001
NRS	8.0±0.8	5.5±1.7	-2.5±1.9	<0.001
HIT-6	67.3±7.6	54.6±10.9	-12.7±11.8	<0.001
MIDAS	102.9±82.5	34.0±36.0	-68.9±64.8	<0.001
MIBS-4	9.5±3.4	4.7±3.8	-4.8±4.2	<0.001

Abbreviations: ∆, difference between baseline and weeks 9–12; MMD monthly migraine days, MHD monthly headache days, MAI analgesic doses taken per month, NRS Numerical Rating Scale, HIT-6 Headache Impact Test-6, MIDAS Migraine Disability Assessment Scale, MIBS-4 Migraine Interictal Burden Scale
^*p-value of post hoc pairwise comparisons in repeated measures analysis

ISSN: 1129-2377